Last reviewed · How we verify
Trimebutine Maleate
At a glance
| Generic name | Trimebutine Maleate |
|---|---|
| Sponsor | Xijing Hospital of Digestive Diseases |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Pharmacokinetics, Bioequivalence, and Safety Study of Trimedat® 76,95 mg Orally Disintegrating Tablets and Trimedat® 100 mg Tablets in Healthy Volunteers. (PHASE1)
- Study to Evaluate the Treatment Benefits of Probiotic Clostridium Butyricum CBM588® for IBS-D (NA)
- Trimebutine Maleate Combined With Rabeprazole in Patients With Grade A or B Reflux Esophagitis Whose Symptoms Refractory to Rabeprazole (PHASE4)
- Comparative Efficacy and Safety of Fenoverine (PHASE4)
- Study of Trimebutine Maleate (NEWBUTIN SR 300 mg Tab)for Treatment of Post Operative Nausea and Vomiting (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Trimebutine Maleate CI brief — competitive landscape report
- Trimebutine Maleate updates RSS · CI watch RSS
- Xijing Hospital of Digestive Diseases portfolio CI